p>
Goodwill 14,844 14,844
Total assets $173,639 $165,245
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $12,626 $10,587
Accrued compensation 8,362 8,573
Accrued royalties 6,791 6,913
Accrued collaboration profit sharing 1,388 522
Accrued and other liabilities 7,290 4,742
Income tax payable - 213
Deferred revenue 2,927 4,016
Total current liabilities 39,384 35,566
Deferred revenue 1,795 2,054
Other liabilities 1,065 690
Total liabilities 42,244 38,310
Shareholders' equity:
Common stock 264,140 254,807
Additional paid-in capital 33,930 26,697
Accumulated other comprehensive income (loss) (2,390) 340
Accumulated deficit (164,285) (154,909)
Total shareholders' equity 131,395 126,935
Total liabilities and shareholders' equity $173,639 $165,245
CEPHEID
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
Six Months Ended
June 30,
2008 2007
'/>"/>SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1.
Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems2.
Cepheid to Present at Thomas Weisel Partners Healthcare Conference3.
Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB4.
Cepheid to Present at William Blair Small-Cap Growth Stock Conference5.
Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference6.
Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System7.
Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results8.
Cepheid Appoints Senior VP, Chief Financial Officer to Management Team9.
Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market10.
Cepheid Reports Fourth Quarter and Full Year 2007 Results11.
Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference